Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 8/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.48 |
| ▸ | CDK2 | P24941 | 8/20 | 0.48 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.46 |
| ▸ | CCND1 | P24385 | 3/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656302 | 0.87 | AGER (0.51) | FFAR2MAPT | |
| SCHEMBL12469108 | 0.82 | FFAR2 (0.50) | FFAR2 | |
| SCHEMBL24072512 | 0.80 | NPC1 (0.46) | FFAR2LMNAMAPT | |
| SCHEMBL30142816 | 0.80 | NPC1 (0.46) | FFAR2LMNAMAPT | |
| SCHEMBL2175131 | 0.78 | RAB9A (0.60) | CCNE1CDK2CDK4CDK1LMNA | |
| SCHEMBL2652269 | 0.78 | FFAR2 (0.57) | FFAR2CCNE1CDK2LMNAMAPT | |
| SCHEMBL1763394 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL1350381 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL966406 | 0.77 | ALOX15 (0.53) | FFAR2CCNE1CDK2CDK4CDK1 | |
| SCHEMBL13158536 | 0.77 | CCNE1 (0.48) | CCNE1CDK2CDK4CDK1CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017027984-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CANCER BY INHIBITING ATG4B AND BLOCKING AUTOPHAGY | SIMON FRASER UNIVERSITY (CA) | 2017-02-23 | — | — | WO | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2547667-A1 | PROCESS FOR THE PRODUCTION OF 2-AMINO-5-FLUOROTHIAZOLE | Takeda California, Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011115758-A1 | PROCESS FOR THE PRODUCTION OF 2-AMINO-5-FLUOROTHIAZOLE | TAKEDA SAN DIEGO, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| EP-1778657-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | Prosidion Ltd. (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016174-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | FFAR2 1145/4885CCNE1 4246/4885CDK2 1708/4885 |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | GCK, KHK, GCKR | FFAR2 557/4885CCNE1 1964/4885CDK2 1042/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | FFAR2 1169/4885CCNE1 4251/4885CDK2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.